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 ORIGINAL INVESTIGATION 
 Effi cacy of  Ginkgo biloba extract EGb 761  ®  in dementia with 
behavioural and psychological symptoms: A systematic review 
 ARMIN  VON GUNTEN 1 ,  SANDRA  SCHLAEFKE 2  &  KARL  Ü BERLA 3 
 1 Service Universitaire de Psychiatrie de l’Age Avanc é (SUPAA), Department of Psychiatry, Centre Hospitalier 
Universitaire Vaudois, Prilly, Switzerland,  2 Dr. Willmar Schwabe GmbH  & Co. KG, Karlsruhe, Germany, and 
 3 Prof. em. for Epidemiology, Ludwig-Maximilian-University, Munich, Germany 
 Abstract 
 Objectives. To review current evidence of effi cacy of  Ginkgo biloba extract EGb 761  ®  in dementia with behavioural and 
psychological symptoms (BPSD).  Methods. Randomized, placebo-controlled trials assessing the effects of EGb 761  ®  in 
dementia patients with BPSD were included if the diagnosis was made in accordance with internationally accepted criteria, 
the treatment period was at least 22 weeks, outcome measures covered BPSD and at least two of the following domains 
of assessment, i.e. cognition, activities of daily living and clinical global assessment, and methodological quality was ade-
quate. An analysis of covariance (ANCOVA) model was used to calculate the pooled effect estimates and to compare effects 
of EGb 761  ®  and placebo; furthermore, combined risk differences of response rates were calculated.  Results. Four published 
trials were identifi ed, involving altogether 1,628 outpatients with mild to moderate dementia. Least-square mean differences 
for change from baseline in cognition, BPSD (including caregiver distress rating), activities of daily living, clinical global 
impression, and quality of life favoured EGb 761  ®  ( P    0.001 for all comparisons).  Conclusions. The pooled analyses provide 
evidence of effi cacy of EGb 761  ®  at a daily dose of 240 mg in the treatment of out-patients suffering from Alzheimer ’ s, 
vascular or mixed dementia with BPSD. 
 Key words:  dementia ,  Alzheimer ’ s disease ,  vascular dementia ,  Ginkgo biloba ,  EGb 761  ®  
 Introduction 
 Population aging and the resulting increased preva-
lence of both Alzheimer’s disease (AD) and vascular 
dementia (VaD) has signifi cant implications world-
wide. It is estimated that the number of people liv-
ing with dementia worldwide (35.6 million in 2010) 
will increase to 65.7 million by 2030 and 115.4 mil-
lion by 2050 (Alzheimer’s Disease International 
2010). There is no cure for dementia, and evidence 
for the effectiveness of preventive measures is 
sparse. 
 Although behavioural and psychological symp-
toms of dementia (BPSD), also referred to as neu-
ropsychiatric symptoms, have been found in 80% 
to nearly 100% of patients with dementia (Stein-
berg et  al. 2008; van der Mussele et  al. 2013), 
patients with such symptoms have been excluded 
from many anti-dementia drug trials, which limits 
the generalizability of the trial results to the actual 
patient population (Schneider et  al. 1997a). It was 
speculated earlier that the presence and severity of 
BPSD, namely depression, might infl uence cogni-
tive abilities and, therefore, treatment-related 
improvements in BPSD (or depression) might indi-
rectly improve cognition. There was concern there-
fore that a drug that actually affects BPSD might 
be falsely considered as an anti-dementia drug 
(Leber 1990). However, Powlishta et  al. (2004) 
have demonstrated that cognitive impairment even 
in very mild AD is driven by the underlying disease 
and its severity is independent of concomitant 
depression. 
 Vascular risk factors such as hypertension and 
stroke are associated with a higher frequency of 
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2 A. von Gunten et al. 
 Methods 
 Data sources 
 We used a sensitive search strategy including the 
following electronic databases: PubMed, including 
MedLine (from beginning to December 2013), 
EMBASE (from January 2006 to December 
2013) and PASCAL (from beginning to December 
2013). The following search terms were used (with 
 * characterizing a wildcard, and the items AND and 
OR being used as Boolean functions):  (ginkg * OR 
gingk * ) AND clinical trial[pt] for PubMed including 
MedLine,  ((ginkg * OR gingk * ) NOT medline[sb]) 
AND (clinical * OR trial OR randomized) for PubMed 
excluding Medline,  (GINKGO OR GINGKO) AND 
(HUMAN/CT OR HOMME/CTFR) for PASCAL, 
and  (ginkgo or gingko) AND CT    (CLINICAL 
TRIAL; CLINICAL STUDY; DOUBLE BLIND 
PROCEDURE) AND py    2005 for EMBASE. Fur-
thermore, the reference sections of systematic 
reviews were screened for primary publications. In 
addition, the manufacturer of EGb 761  ®  , Dr. Will-
mar Schwabe GmbH  & Co. KG was asked about 
studies that were not identifi ed by the search or had 
not been published when the search was per-
formed. 
 Selection and critical appraisal of clinical trials 
 Randomized, placebo-controlled, double-blind clini-
cal trials assessing the effects of an oral dosage form 
of EGb 761  ®  in patients with the diagnosis of AD, 
VaD or mixed dementia (i.e. with features of both 
AD and cerebrovascular disease) of at least 22 weeks ’ 
duration were selected, if (a) the patients enrolled 
were diagnosed with dementia in accordance with 
internationally accepted diagnostic criteria (Diagnos-
tic and Statistical Manual of Mental Disorders III-R 
and IV [DSM-III-R, DSM-IV (APA 1987, 1994)], 
International Classifi cation of Diseases 10 [ICD-10 
(WHO 1992)], National Institute of Neurological 
and Communicative Disorders and Stroke and 
Alzheimer ’ s Disease and Related Disorders Associa-
tion [NINCDS-ADRDA (McKhann et  al. 1984)], or 
the National Institute for Neurological Disorders and 
Stroke and Association Internationale pour la Recher-
che et l ’ Enseignement en Neuroscience [NINDS/
AIREN (Rom á n et  al. 1993)]); (b) had clinically sig-
nifi cant BPSD as defi ned by minimal scores on the 
Neuropsychiatric Inventory (NPI, Cummings 1997) 
or other appropriate rating scales; (c) outcome mea-
sures were defi ned for BPSD and at least two of the 
three typical domains of assessment: cognition, activ-
ities of daily living (ADL), and clinical global assess-
ment; and (d) methodological quality was adequate. 
BPSD (Treiber et  al. 2008). The presence of BPSD 
is associated with a faster progression to severe 
dementia (Rabins et  al. 2013) and has a negative 
impact on the patients ’ quality of life (Banerjee et  al. 
2009; Karttunen et  al. 2011). Clinical trials of EGb 
761  ®  and an earlier systematic review found BPSD 
to be effect modifi ers in the treatment of dementia 
(Schneider et  al. 2005; Ihl et  al. 2010; Janssen et  al. 
2010). The biological mechanisms underlying this 
effect are not fully understood, but they may be 
related to vascular effects of EGb 761  ®  . Conse-
quently, some of the recent trials of  Ginkgo biloba 
extract EGb 761  ®  specifi cally enrolled patients with 
BPSD. 
 EGb 761  ®  is one of the anti-dementia drugs with 
proven benefi ts (Janssen et  al. 2010; Weinmann 
et  al. 2010) that is recommended by international 
guidelines for the symptomatic treatment of demen-
tia (Ihl et  al. 2011b). An earlier Cochrane Review 
(Birks and Grimley Evans 2007) came to a less 
favourable conclusion, but that review included 
studies of different Ginkgo products in patients with 
a variety of conditions (subjective complaints, mild 
cognitive defi cits, full-blown dementia), and the 
three latest trials in dementia with BPSD were not 
available yet when it was conducted. EGb 761  ®  * 
has a multi-factorial pharmacodynamic profi le. It 
preserves and improves mitochondrial function and 
energy metabolism, promotes hippocampal neuro-
genesis and neuroplasticity and enhances cerebral 
blood fl ow by decreasing blood viscosity (M ü ller 
et  al. 2012; Lang et  al. 2013). With data from two 
further randomized, placebo-controlled trials that 
were not available at the time of Janssen et  al. ’ s 
(2010) review, there is now a solid database for a 
systematic review and pooled data analysis specifi -
cally addressing the question of effi cacy and safety 
of EGb 761  ®  in patients with dementia who have 
clinically signifi cant BPSD. With nearly identical 
inclusion and exclusion criteria in these clinical tri-
als, the data could be pooled. Since the majority of 
patients with dementia exhibit BPSD (Petrovic 
et  al. 2007; Steinberg et  al. 2008; Di Iulio et  al. 
2010; Van der Mussele et  al. 2013), they represent 
the core target group for anti-dementia drug treat-
ment in general, as well as for the treatment of 
BPSD, in particular. 
*EGb 761® is a dry extract from Ginkgo biloba leaves (35-67:1), 
extraction solvent: acetone 60% (w/w). The extract is adjusted to 
22.0 – 27.0% ginkgo fl avonoids calculated as ginkgo fl avone 
glycosides and 5.0 – 7.0% terpene lactones consisting of 2.8 – 
3.4% ginkgolides A, B, C and 2.6 – 3.2% bilobalide and contains 
less than 5 ppm ginkgolic acids. EGb 761® is a registered 
trademark of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, 
Germany.
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EGb 761 ®  in dementia with BPSD        3
effect sizes of 0.2 / 0.5 / 0.8 were classifi ed as small 
/ moderate / large effects, respectively. 
 Response rates for EGb 761  ®  in all domains were 
compared to placebo in this analysis, as far as the 
same outcome measures were available for the 
selected clinical trials. Overall effects for response 
rates calculated using a fi xed effects model and the 
Mantel-Haenszel method, are expressed as risk dif-
ferences with 95% confi dence intervals. In addition, 
numbers needed to treat (NNTs) with 95% confi -
dence intervals were calculated using the overall risk 
differences. 
 Statistical signifi cance is assumed with  P    0.05. 
All analyses were based on the entire patient sample 
and different types of dementia. SAS  ®  package 
(release 9.2) running on a personal computer was 
used for the analyses of continuous variables and the 
calculation of NNTs with 95% confi dence intervals. 
The meta-analyses of response rates were performed 
using Review Manager, version 5 (The Cochrane 
Collaboration, Oxford, England). 
 Results 
 Clinical trial characteristics 
 Four trials identifi ed by database searches (Napry-
eyenko and Borzenko 2007; Ihl et  al. 2011a; 
Herrschaft et  al. 2012; Nikolova et  al. 2013) met our 
inclusion criteria. Six trials that were included in the 
review by Weinmann et  al. (2010) were excluded 
from the present meta-analysis, because the patients 
enrolled were not required to have BPSD and BPSD, 
if present, were not quantifi ed. All eligible trials used 
the defi ned extract EGb 761  ®  at daily doses of 
240 mg. There was no clinical trial with another 
ginkgo product that met our inclusion criteria. One 
trial was performed in Bulgaria (Nikolova et  al. 
2013), two in Ukraine (Ihl et  al. 2011a; Napryey-
enko and Borzenko 2007) and one in three countries 
(Republic of Belarus, Republic of Moldova, and 
Russian Federation) (Herrschaft et  al. 2012). 
 All trials included outpatients selected by the fol-
lowing inclusion criteria: 
(a)  mild to moderate dementia; tests used in the 
four trials comprised the TE4D screening 
test for dementia (Mahoney et  al. 2005) and 
the SKT short cognitive performance test 
(Erzigkeit 1992; Kim et  al. 1993). The total 
score in the TE4D was always    35 and the 
total score in the SKT was between 9 and 
23. These values correspond roughly to the 
range from 14 to 25 on the Mini-Mental 
State Examination or 17 to 35 on the cogni-
The methodological quality of the trials was consid-
ered adequate, if (a) randomization, allocation con-
cealment and blinding, (b) sample size estimation, (c) 
numbers and disposition of patients who discontin-
ued the trial prematurely, and (d) statistical analyses 
were reported and judged adequate. 
 Statistical analysis 
 This pooled data analysis is based on individual 
patient data. The sponsor, Dr. Willmar Schwabe 
GmbH  & Co. KG provided the pertinent data from 
all selected studies. For each of the four clinical tri-
als, the effects of EGb 761  ®  with respect to the 
domains cognition, BPSD, activities of daily living, 
and quality of life were compared to placebo using 
an analysis of covariance (ANCOVA) model. The 
ANCOVA model includes terms for treatment group 
and baseline value of respective outcome variable as 
covariate. Analysis of the clinical global assessment 
does not include baseline values since they are not 
available for all clinical trials. In this case, an analy-
sis of variance (ANOVA) model with a term for 
treatment group was used. If different outcomes 
were used in different trials, outcomes (change scores 
and baseline values, if included in the model) were 
standardised within each clinical trial by dividing 
scores by the between patient standard deviation to 
create a dimensionless measure (Higgins et  al. 2001). 
In the case of missing values for the outcome vari-
ables, the last observation during randomised treat-
ment was carried forward (LOCF). Treatment effects 
in single trials are presented as differences of (stan-
dardised) least square means (or differences of stan-
dardised means for clinical global assessment) with 
95% confi dence intervals, respectively. 
 The design of all clinical trials was very similar 
with regard to inclusion and exclusion criteria, and 
duration of treatment. The effects of EGb 761  ®  with 
respect to the domains cognition, BPSD, activities of 
daily living, and quality of life were compared to 
placebo using ANCOVA. The ANCOVA models 
included terms for clinical trial, treatment group and 
baseline value of the outcome variable as covariate. 
Clinical global assessment was analysed using an 
ANOVA model with terms for clinical trial and treat-
ment group. Overall effect size measured by rating 
scales is expressed as standardised least square mean 
differences or least square mean differences if appro-
priate for the comparison (same outcome in every 
clinical trial) with 95% confi dence intervals. In order 
to compare overall effect sizes with results of other 
analyses standardised mean differences (Cohen ’ s  D ) 
are reported in addition to the least square mean 
differences. According to Cohen (1988), standardised 
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4 A. von Gunten et al. 
SKT total score varied between 15 (Nikolova et  al. 
2013; Herrschaft et  al. 2012) and 17 points (Ihl et  al. 
2011a). The highest NPI total score and NPI distress 
score were observed in Napryeyenko and Borzenko 
(2007) with mean values of about 21 and 13 points, 
respectively. In the other trials the mean NPI 
total score and the mean NPI distress score were 
about 17 and 10 points, respectively. The mean of 
the GBS-ADL (ADL subscale of the Gottfries-
Br å ne-Steen (GBS, Br å ne et  al. 2001)) was higher 
in Napryeyenko and Borzenko ’ s (2007) than in 
Nikolova et  al. ’ s (2013) study. The same holds true 
for the mean of the GBS total score. Mean scores of 
the ADL-IS were similar in the treatment groups as 
well as across trials (Ihl et  al. 2011a; Herrschaft et  al. 
2012). 
 Clinical outcomes 
 Mean changes (with standard deviations) from base-
line to end of treatment are presented for clinical 
outcomes in fi ve domains of assessment: cognition, 
BPSD, ADL, global rating and quality of life (QoL). 
For all outcome measures except the QoL scale, 
negative mean change scores indicate improvement 
and negative estimates of treatment effects indicate 
a larger effect of EGb 761  ®  compared to placebo. 
For the QoL scale, positive changes of the total score 
show an improvement, positive estimates of treat-
ment effects favour EGb 761  ®  . 
 Cognition 
 In all trials, the SKT short cognitive performance 
test was used for cognitive assessment. In three tri-
als, cognition improvement was signifi cantly supe-
rior in patients treated with EGb 761  ®  than with 
placebo. Pooled analysis resulted in an overall mean 
change score of SKT of  – 2.26    3.15 for EGb 761  ®  
tive subscale of the Alzheimer’s Disease 
Assessment Scale (Ihl et  al. 1999); 
(b)  either probable AD according to NINCDS/
ADRDA, or probable vascular dementia 
according to NINDS/AIREN, or mixed 
dementia (possible Alzheimer’s disease with 
cerebrovascular disease according to the 
respective sub-criteria of NINCDS/ADRDA 
and NINDS/AIREN); all trials included 
used these criteria; 
(c)  clinically signifi cant BPSD (NPI total 
score    5), but no severe or major depression 
(total score on the 17-item Hamilton Rating 
Scale for Depression    20 (Hamilton 1960)); 
and age    50. The duration of treatment var-
ied between 22 (Nikolova et  al. 2013; Napry-
eyenko and Borzenko 2007) and 24 weeks 
(Ihl et  al. 2011a; Herrschaft et  al. 2012). 
 Sample sizes and demographic characteristics of 
patient populations are presented in Table I. In total, 
1628 patients were randomised, 814 patients to each 
treatment group. Drop-out rates were low and simi-
lar in both treatment groups in all trials. Out of the 
1628 randomised patients 1598 (EGb 761  ®  : 796; 
placebo: 802) were evaluable with respect to effi cacy 
(Full Analysis Set, FAS). The FAS included (a) all 
randomised patients who received at least one dose 
of the study drug and had at least one effi cacy assess-
ment after baseline, and (b) all randomised patients 
who had discontinued prematurely due to an adverse 
event potentially related to the drug under investiga-
tion. Demographic characteristics were well bal-
anced across treatment groups in each trial. In the 
trial of Nikolova et  al. (2013), about 10% fewer 
women were included and the patients were about 
4 years older compared to the other trials. 
 Baseline scores of all outcome measures are pre-
sented in Table II. They were well balanced across 
treatment groups in each trial. The means of the 
 Table I. Characteristics of trial populations. 
Clinical trial, author, date
Treatment 
groups
Randomized 
[ N ]
Drop-Outs 
[ N ] (%) 1 
FAS 
[ N ]
Female 
[%]
Age [years] 
Mean (SD)
Nikolova et  al. 2013 EGb 761  ®  203 13 (6) 196 57 69 (8)
Placebo 205 17 (8) 201 60 69 (8)
Napryeyenko and Borzenko 2007 EGb 761  ®  200 4 (2) 198 72 65 (8)
Placebo 200 5 (3) 197 72 63 (8)
Ihl et  al. 2011a EGb 761  ®  206 16 (8) 202 69 65 (10)
Placebo 204 12 (6) 202 66 65 (9)
Herrschaft et  al. 2012 EGb 761  ®  205 7 (3) 200 70 65 (9)
Placebo 205 7 (3) 202 69 65 (9)
Total EGb 761  ®  814 40 (5) 796 67 66 (9)
Placebo 814 41 (5)) 802 68 66 (9)
 1 Percent of randomized patients. 
 FAS, full analysis set (includes all patients valid for effi cacy evaluation. 
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change of NPI total scores in the four clinical trials 
lumped together (1598 patients: 796; 802) were 
reduced by at least 3 points in all EGb 761  ®  -treated 
groups (Figure 2A). In three trials patients ’ mean 
change in NPI total and NPI caregiver distress scores 
improved signifi cantly with EGb 761  ®  compared to 
placebo. 
 Pooled analysis resulted in an overall mean change 
of NPI total score of  – 4.52    6.56 with EGb 761  ®  
and  – 0.71    6.94 with placebo. This corresponds to 
a standardised mean difference of  – 0.56 (Cohen ’ s 
 D ). The least square mean difference was  – 3.85 
(95% CI [ – 4.50;  – 3.21];  P    0.001) (Figure 2A). 
Mean change NPI caregiver distress score pooled 
and of  – 0.20    3.48 for placebo treatment. This 
corresponds to a standardised mean difference of 
 – 0.62 (Cohen ’ s  D ). The least square mean differ-
ence was  – 2.08 ( 95% CI [ – 2.40;  – 1.76];  P    0.001). 
This is roughly equivalent to a mean difference of 
 – 2.7 on the ADAS-cog (Ihl et  al. 1999). A signifi -
cant difference was confi rmed in favour of EGb 
761  ®  (Figure 1). 
 Behavioural and psychological symptoms (BPSD) 
 All trials used the NPI total score and the NPI care-
giver distress score for the assessment of BPSD and 
BPSD-related caregiver distress, respectively. Mean 
 Table II. Baseline scores of clinical outcome measures [mean/(SD)]. 
Clinical trial
Treatment 
groups  N 1 
Cognition 
(SKT) 
[Mean (SD)] 
(range 0 – 27)
NPI total 
score 
[Mean (SD)] 
(range 0 – 144)
NPI Distress 
[Mean (SD)] 
(range 0 – 60)
ADL scale 
[Mean (SD)]
Global 
assessment 
[Mean (SD)]
Quality of Life 
[Mean (SD)]
 GBS-ADL 
 (Range 0 – 36) 
 GBS-total 
score 
 (Range 
0 – 126) 
Nikolova 2013 EGb 761  ®  196 14.9 (4.3) 17.1 (9.5) 10.1 (6.4) 2.3 (3.4) 26.0 (13.1)  – 
Placebo 201 15.4 (4.2) 16.9 (8.7) 9.5 (5.2) 2.6 (3.6) 26.7 (12.7)  – 
 GBS-ADL  GBS-total 
score 
Napryeyenko 
and Borzenko 
2007
EGb 761  ®  198 15.6 (3.9) 21.3 (9.5) 13.5 (6.7) 4.8 (3.9) 35.3 (9.1)  – 
Placebo 197 15.4 (3.7) 21.6 (9.9) 13.4 (6.4) 4.9 (4.1) 34.3 (8.7)  – 
 ADL-IS 
 (Range 0 – 4) 
 ADCS-CGIC  (DEMQOL-
PROXY) 
 Range(31 – 124) 
Ihl et  al. 2011a EGb 761  ®  202 16.7 (3.9) 16.4 (8.1) 9.6 (5.6) 1.9 (0.6)  – 87.9 (11.7)
Placebo 202 17.2 (3.7) 17.0 (8.2) 10.0 (5.4) 2.0 (0.5)  – 88.0 (10.9)
 ADL-IS  ADCS-CGIC  (DEMQOL-
PROXY) 
Herrschaft et  al. 
2012
EGb 761  ®  200 15.1 (4.1) 16.8 (6.9) 10.2 (5.3) 1.7 (0.6)  – 85.7 (10.6)
Placebo 202 15.3 (4.2) 16.7 (6.4) 10.1 (5.1) 1.8 (0.6)  – 86.0 (10.3)
 1 N includes all patients valid for evaluation of effi cacy (FAS). 
 Figure 1. Changes of SKT total scores based on the full analysis set (FAS). 
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and two trials (Ihl et  al. 2011a; Herrschaft et  al. 
2012) used the Activities-of-Daily-Living Interna-
tional Scale (ADL-IS, Reisberg et  al. 2001) to eval-
uate ADL. 
 Data from four clinical trials (1598 patients: 
796; 802) are presented for activities of daily living. 
In all trials, activities of daily living improved more 
in patients actively treated than in those receiving 
placebo. 
 Pooled analysis of all four trials resulted in a mod-
erate standardised least square mean difference of 
 – 0.56 (95% CI [ – 0.66;  – 0.46];  P    0.001). A signifi -
cant difference was confi rmed in favour of EGb 
761  ®  (Figure 3). 
analysis resulted in  – 2.64    4.44 with EGb 761  ®  and 
 – 0.33    3.98 with placebo. This corresponds to a 
standardised mean difference of  – 0.55 (Cohen ’ s  D ). 
The least square mean difference was  – 2.30 (95% 
CI [ – 2.68;  – 1.91];  P    0.001) (Figure 2B). A signifi -
cant difference was confi rmed in favour of EGb 
761  ®  for both NPI evaluations. 
 Activities of Daily Living (ADL) 
 Two trials (Nikolova et  al. 2013; Napryeyenko and 
Borzenko 2007) used the ADL subscale of the 
Gottfries-Br å ne-Steen scale (GBS, Br å ne et  al. 2001) 
 Figure 2. Changes of NPI total scores [A] and caregiver distress scores [B] based on the full analysis set (FAS). 
 Figure 3. Changes of ADL scores (GBS-ADL, ADL-IS) based on the full analysis set (FAS). 
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 Pooled analysis resulted in an overall mean change 
of 3.42    8.76 for EGb 761  ®  and 1.43    7.65 for 
placebo treatment. This corresponds to a stan-
dardised mean difference of 0.24 (Cohen ’ s  D ). The 
least square mean difference was 1.94 (95% CI 
[0.92; 2.96];  P    0.001). A signifi cant difference was 
confi rmed in favour of EGb 761  ®  (Figure 5). 
 Subgroup analyses 
 Subgroup analyses revealed statistically signifi cant 
superiority of EGb 761  ®  for all outcome measures 
in all three diagnostic subgroups (probable AD, 
probable vascular dementia, mixed dementia), except 
QoL in the very small VaD subgroup (Table III). 
 Responder analysis 
 Response criteria were chosen on the basis of obvi-
ous clinical relevance and published expert consen-
sus. In the cognitive domain, an improvement by 4 
points on the ADAS-cog is generally regarded as 
clinically relevant (Rogers et  al. 1998). According to 
regression analyses performed by Ihl et  al. (1999), a 
3-point change in the SKT corresponds to a 3.9-
point change in the ADAS-cog and can thus be con-
sidered as a clinically relevant change. According to 
 Clinical global impression of change from baseline 
 Two trials (Napryeyenko and Borzenko 2007; 
Nikolova et  al. 2013) used the GBS total score and 
two trials (Ihl et  al. 2011a; Herrschaft et  al. 2012) 
used the Alzheimer’s Disease Cooperative Study 
Clinical Global Impression of Change (ADCS-
CGIC, Schneider et  al. 1997b) for the clinical global 
rating of change from baseline. 
 In all trials, the global impression of change from 
baseline was rated better for patients treated with EGb 
761  ®  compared with placebo. In three trials (Napry-
eyenko and Borzenko 2007; Ihl et  al. 2011a; Herrschaft 
et  al. 2012) the differences between the treatment 
groups were statistically signifi cant (Figure 4). 
 Pooled analysis resulted in a moderate to large 
standardised MEAN-difference of  – 0.75 (95% CI 
[ – 0.85;  – 0.65];  P    0.001). A signifi cant difference 
was confi rmed in favour of EGb 761  ®  (Figure 4). 
 Quality of Life 
 Health-related QoL was evaluated in two clinical tri-
als (806 patients: 402; 404) (Ihl et  al. 2011a; Herrschaft 
et  al. 2012) using DEMQOL-PROXY total mean 
score (Smith et al. 2005). In both trials, quality of life 
mean improvement was signifi cantly superior in 
patients with EGb 761  ®  than with placebo. 
 Figure 5. Changes of DEMQOL-PROXY total score based on the full analysis set (FAS). 
 Figure 4. Clinical global assessment (change scores of GBS-total score, ADCS-CGIC) based on the full analysis set (FAS). 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
ire
 D
e L
au
sa
nn
e] 
at 
05
:34
 31
 A
ug
us
t 2
01
5 
8 A. von Gunten et al. 
as this leap corresponds to a change either from 
moderate to mild impairment or from mild to no 
impairment in four of twelve cognitive functions,. 
 The results of the responder analyses are shown 
in Table IV. Statistically signifi cant superiority of 
EGb 761  ®  compared to placebo could be demon-
strated for all response criteria. The NNTs ranged 
from 4 to 5. 
 Safety and tolerability 
 Across the four trials, 821 adverse events in 
479 patients taking EGb 761  ®  and 998 adverse events 
in 488 patients receiving placebo were reported. 
Eighteen serious adverse events were reported by 18 
an expert consensus, an improvement by 4 points in 
NPI total score is considered clinically relevant 
(Mega et  al. 1999). Regarding activities of daily liv-
ing, any improvement that is perceived by a caregiver 
or other observer after 5 – 6 months is clinically rel-
evant, at least in patients with a naturally progressive 
type of dementia, such as AD. Similarly, any improve-
ment after 5 – 6 months in a patient’s condition that 
is perceived by a clinician not involved in a patient’s 
treatment and not knowing the results of tests and 
rating scales can be considered as clinically relevant. 
Regarding the structured global rating scale (GBS 
total score), there is no generally accepted relevance 
criterion. Therefore, improvement by approximately 
25% (8 points) was chosen as a response criterion 
 Table III. Aggregated outcomes for diagnostic subgroups; mean changes from baseline with standard 
deviations; LS mean differences (SKT, NPI, DEMQOL-Proxy), standardised LS mean differences 
(GBS-ADL, ADL-IS) or standardised mean differences (GBS total score, ADCS-CGIC) and 95% 
confi dence intervals. 
Outcome measure/ 
Subgroup
EGb 761  ®  N /
Mean/SD Placebo  N /Mean/SD
(Standardised) 
(LS) mean 
difference/95% CI
SKT total score
Probable AD 279  	 1.86 3.11 281  	 0.41 3.41  	 1.50 [ 	 2.03; 	 0.98]
Probable VaD 188  	 2.42 2.79 186 0.07 3.18  	 2.60 [ 	 3.20; 	 2.00]
Mixed type 329  	 2.52 3.35 335  	 0.16 3.69  	 2.35 [ 	 2.88; 	 1.82]
NPI total score
Probable AD 279  	 4.50 6.62 281  	 0.65 7.32  	 3.72 [ 	 4.81; 	 2.62]
Probable VaD 188  	 5.01 6.64 186  	 0.27 6.85  	 4.84 [ 	 6.21; 	 3.46]
Mixed type 329  	 4.26 6.47 335  	 1.00 6.66  	 3.37 [ 	 4.34; 	 2.39]
NPI caregiver distress score
Probable AD 279  	 2.20 4.30 281  	 0.32 4.43  	 1.84 [ 	 2.52; 	 1.17]
Probable VaD 188  	 3.57 4.52 186  	 0.12 3.86  	 3.36 [ 	 4.19; 	 2.54]
Mixed type 329  	 2.48 4.44 335  	 0.45 3.63  	 2.11 [ 	 2.68; 	 1.53]
ADL score
Probable AD 279  	 0.05 1.35 281 0.22 1.31  	 0.35 [ 	 0.51; 	 0.19]
Probable VaD 188  	 1.21 2.37 186 0.49 2.36  	 0.80 [ 	 1.02; 	 0.57]
Mixed type 329  	 0.58 1.86 335 0.26 1.52  	 0.61 [ 	 0.75; 	 0.46]
Clinical Global Assessment
Probable AD 278 1.07 5.97 278 2.73 5.59  	 0.52 [ 	 0.69; 	 0.36]
Probable VaD 188  	 4.79 9.18 184 3.12 7.27  	 1.08 [ 	 1.30; 	 0.86]
Mixed type 327  	 1.12 8.10 335 2.97 5.43  	 0.77 [ 	 0.92; 	 0.61]
DEMQOL-Proxy
Probable AD 171 3.40 8.83 158 0.27 7.00 2.40 [0.85;3.95]
Probable VaD 59 3.31 9.17 54 2.63 7.65 0.74 [ 	 2.17;3.64]
Mixed type 172 3.48 8.60 192 2.06 8.05 1.90 [0.36;3.44]
 Table IV. Summary of results of the responder analysis. 
Response Trials  N 
Difference of response 
rates and 95% CI
NNT and 
95% CI
Improvement SKT    3 points 4 1589 0.25 [0.21; 0.29] 4 [4; 5]
Improvement NPI total score    4 points 4 1589 0.28 [0.24; 0.33] 4 [4; 5]
Improvement GBS-ADL 2 792 0.24 [0.18; 0.30] 5 [4; 6]
Improvement ADL-IS 2 806 0.28 [0.22; 0.35] 4 [3; 5]
Improvement GBS total score    8 2 792 0.32 [0.27; 0.38] 4 [3; 4]
Improvement ADCS-CGIC 2 806 0.30 [0.23; 0.36] 4 [3; 5]
 N , total number of patients included in the meta-analysis; CI, confi dence interval; NNT, number needed 
to treat. 
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refl ect continued improvements in overall care for 
dementia patients at the clinical sites while the 
study was running. 
 The pooled analyses were performed using stan-
dard methods. Since the analysed clinical trials were 
very similar with respect to study design, patient 
selection and duration of treatment, an ANCOVA was 
used to compare the effects of EGb 761  ®  and placebo. 
Other reviews have been conducted in the evaluation 
of drugs in neurology and psychiatry, including anti-
dementia drugs, using similar methods (Stacey et  al. 
2004; Gauthier et  al. 2008; Beesdo et  al. 2009). 
 All studies included patients with AD, VaD or 
dementia with mixed AD/VaD pathology. The clini-
cal researchers give reasons for this, pointing out that 
EGb 761  ®  interferes with both AD and vascular 
pathologies (Lang et  al. 2013) and that, irrespective 
of the attributed clinical diagnosis, mixed pathology 
has been found in neuropathology studies to be more 
prevalent than AD or VaD alone (Matthews et  al. 
2009; Schneider et  al. 2007). Nevertheless, clinical 
diagnoses in accordance with internationally accepted 
criteria (NINCDS/ADRDA, NINDS/AIREN) were 
established prospectively at patient screening in all 
studies, which allowed meta-analyses for the differ-
ent diagnostic subgroups. For all three subgroups 
signifi cant superiority of EGb 761  ®  over placebo was 
found in all but one outcome measure as there was 
no signifi cant effect on QoL in the VaD subgroup. It 
can only be speculated whether this was due to a lack 
of statistical power in this very small subsample, or 
perhaps to different determinants of QoL, e.g. stroke-
related neurological defi cits, in VaD. 
 Whereas earlier trials (Le Bars et  al. 2000, Kanowski 
and Hoerr 2003) suggested slightly stronger treatment 
effects of EGb 761  ®  in patients with AD, this notion 
is not supported by the present analyses of trials in 
patients with clinically signifi cant BPSD. DSM-III-R 
diagnostic criteria (APA 1987) for multiple-infarct 
dementia, that were applied in the earlier trials, and 
the NINDS-AIREN criteria for probable VaD (Rom á n 
et  al. 1993) applied in the later trials may have selected 
somewhat different types of VaD patients. 
 The effect sizes for cognition, ADL, BPSD (NPI 
total and caregiver distress scores) and clinical global 
impression were overall moderate, for QoL a small 
effect size was observed. Weinmann et  al. (2010), 
who included in their meta-analysis studies in 
patients without clinically signifi cant BPSD, reported 
a similar effect size for cognition (Cohen’s  D of 
 – 0.58), but a clearly smaller effect size for ADL 
(Cohen’s  D of  – 0.32). The reason for the difference 
may be that both cognitive impairment and BPSD 
presumably contribute to ADL impairment and 
improvements in both domains may lead to a larger 
improvement in ADL. 
patients treated with EGb 761  ®  and 22 serious 
adverse events were documented for 20 patients tak-
ing placebo (Table V). There was no clustering of any 
type of event in the EGb 761  ®  treated patients. 
 Discussion 
 The present pooled analysis provides evidence of the 
effi cacy of  Ginkgo biloba extract EGb 761  ®  at a daily 
dose of 240 mg in the treatment of dementia patients 
with clinically relevant BPSD. Active drug treatment 
was statistically and clinically signifi cantly superior 
to placebo in improving patients ’ cognitive perfor-
mance, BPSD, functional abilities and overall condi-
tion. As a consequence, the distress perceived by 
caregivers due to the patients ’ BPSD was alleviated. 
Rates of adverse events and serious adverse events 
did not differ between EGb 761  ®  and placebo. 
 Signifi cant superiority of EGb 761  ®  was seen in 
three of the four trials and in the pooled analysis, 
while in one trial (Nikolova et  al. 2013) drug – 
placebo differences, although favouring active treat-
ment, were small and not statistically signifi cant. 
Patients in this trial seemed to have milder overall 
pathology and ADL impairment, although their 
cognitive abilities assessed by the SKT and the 
severity of their BPSD were similar to those of the 
patients enrolled in the other trials. There were, 
however, considerable improvements in placebo-
treated patients which increased during the study 
period and, according to the authors, are likely to 
 Table V. Numbers of serious adverse events under EGb 761  ®  and 
placebo treatment, respectively. 
Event
EGb 761  ®  
( n    814)
Placebo 
( n    814)
Angina pectoris 6 11
Arrhythmia 1 0
Acute cardiac failure 1 0
Caridac arrest 1 0
Hemiparesis 1 1
Hypoesthesia 0 1
Aphasia 0 1
Vertebrobasilar insuffi ciency 1 0
Cerebrovascular accident 1 0
Transitory ischaemic attack 1 0
Ischaemic stroke 1 1
Haemorrhagic stroke 0 1
Vascular encephalopathy 0 1
Head injury 0 1
Agitation 0 1
Pneumonia 0 2
Viral infection 1 0
Erosive gastritis 1 0
Femur fracture 0 1
Breast cancer 1 0
Lung cancer 1 0
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10 A. von Gunten et al. 
total scores around 35. There are, however, no trials 
of EGb 761  ®  in in-patients with severe BPSD. 
 Overall, the present pooled analysis demonstrates 
that  Ginkgo biloba extract EGb 761  ®  is both safe and 
moderately effective in the treatment of out-patients 
suffering from dementia with mild to moderate 
behavioural and psychological symptoms. 
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